Journal of Surgery Concepts & Practice ›› 2022, Vol. 27 ›› Issue (01): 25-29.doi: 10.16139/j.1007-9610.2022.01.007
• Experts forum • Previous Articles Next Articles
WU Lilia, XU Yaolinb, LOU Wenhuib()
Received:
2021-12-22
Online:
2022-01-25
Published:
2022-03-17
CLC Number:
WU Lili, XU Yaolin, LOU Wenhui. Radiotherapy in management of pancreatic cancer: application and prospect[J]. Journal of Surgery Concepts & Practice, 2022, 27(01): 25-29.
[1] |
Cai J, Chen H, Lu M, et al. Advances in the epidemiology of pancreatic cancer: Trends, risk factors, screening, and prognosis[J]. Cancer Letters, 2021, 520:1-11.
doi: 10.1016/j.canlet.2021.06.027 URL |
[2] |
Kalser MH, Ellenberg SS. Pancreatic cancer. adjuvant combined radiation and chemotherapy following curative resection[J]. Arch Surg, 1985, 120(8):899-903.
doi: 10.1001/archsurg.1985.01390320023003 URL |
[3] |
Gastrointestinal Tumor Study Group. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer[J]. Cancer, 1987, 59(12):2006-2010.
doi: 10.1002/1097-0142(19870615)59:12<2006::AID-CNCR2820591206>3.0.CO;2-B URL |
[4] |
Smeenk HG, van Eijck CH, Hop WC, et al. Long-term survival and metastatic pattern of pancreatic and periampullary cancer after adjuvant chemoradiation or observation: long-term results of EORTC trial 40891[J]. Ann Surg, 2007, 246(5):734-740.
pmid: 17968163 |
[5] |
Klinkenbijl JH, Jeekel J, Sahmoud T, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase Ⅲ trial of the EORTC gastrointestinal tract cancer co-operative group[J]. Ann Surg, 1999, 230(6):776-782.
pmid: 10615932 |
[6] |
Regine WF, Winter KA, Abrams R, et al. Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase Ⅲ trial[J]. Ann Surg Oncol, 2011, 18(5):1319-1326.
doi: 10.1245/s10434-011-1630-6 URL |
[7] |
Regine WF, Winter KA, Abrams RA, et al. Fluorouracil vs. gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial[J]. JAMA, 2008, 299(9):1019-1026.
doi: 10.1001/jama.299.9.1019 URL |
[8] |
Rutter CE, Park HS, Corso CD, et al. Addition of radiotherapy to adjuvant chemotherapy is associated with improved overall survival in resected pancreatic adenocarcinoma: an analysis of the national cancer data base[J]. Cancer, 2015, 121(23):4141-4149.
doi: 10.1002/cncr.29652 URL |
[9] |
Hsu CC, Herman JM, Corsini MM, et al. Adjuvant chemoradiation for pancreatic adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic collaborative study[J]. Ann Surg Oncol, 2010, 17(4):981-990.
doi: 10.1245/s10434-009-0743-7 URL |
[10] |
Neoptolemos JP, Stocken DD, Friess H, et al. A rando-mized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer[J]. N Engl J Med, 2004, 350(12):1200-1210.
doi: 10.1056/NEJMoa032295 URL |
[11] |
Neoptolemos JP, Dunn JA, Stocken DD, et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial[J]. Lancet, 2001, 358(9293):1576-1585.
pmid: 11716884 |
[12] |
van Laethem JL, Hammel P, Mornex F, et al. Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012/FFCD-9203/GERCOR phase Ⅱ study[J]. J Clin Oncol, 2010, 28(29):4450-4456.
doi: 10.1200/JCO.2010.30.3446 URL |
[13] | Naffouje SA, Sabesan A, Kim DW, et al. Adjuvant chemoradiotherapy in resected pancreatic ductal adenocarcinoma: where does the benefit lie? a nomogram for risk stratification and patient selection[J]. J Gastrointest Surg, 2021-09-10[online ahead of print]. |
[14] |
Abrams RA, Winter KA, Regine WF, et al. Failure to adhere to protocol specified radiation therapy guidelines was associated with decreased survival in RTOG 9704--a phaseⅢ trial of adjuvant chemotherapy and chemoradiotherapy for patients with resected adenocarcinoma of the pancreas[J]. Int J Radiat Oncol Biol Phys, 2012, 82(2):809-816.
doi: 10.1016/j.ijrobp.2010.11.039 URL |
[15] | 中华医学会外科学分会胰腺外科学组. 中国胰腺癌诊治指南(2021)[J]. 中华外科杂志, 2021, 59(7):561-577. |
[16] | Palta M, Godfrey D, Goodman KA, et al. Radiation therapy for pancreatic cancer: executive summary of an ASTRO Clinical Practice Guideline[J]. Pract Radiat On-col, 2019, 9(5):322-332. |
[17] |
Khorana AA, Mangu PB, Berlin J, et al. Potentially cu-rable pancreatic cancer: American Society of Clinical Oncology Clinical Practice Guideline[J]. J Clin Oncol, 2016, 34(21):2541-2556.
doi: 10.1200/JCO.2016.67.5553 pmid: 27247221 |
[18] |
Tempero MA, Malafa MP, Al-Hawary M, et al. Pancreatic adenocarcinoma, version 2.2021, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2021, 19(4):439-457.
doi: 10.6004/jnccn.2021.0017 URL |
[19] | Cohen SJ, Dobelbower RJ, Lipsitz S, et al. A randomized phaseⅢ study of radiotherapy alone or with 5-fluorouracil and mitomycin-C in patients with locally advanced adenocarcinoma of the pancreas: Eastern Co-operative Oncology Group study E8282[J]. Int J Radiat On-col Biol Phys, 2005, 62(5):1345-1350. |
[20] | The Gastrointestinal Tumor Study Group. A multi-institutional comparative trial of radiation therapy alone and in combination with 5-fluorouracil for locally unresectable pancreatic carcinoma[J]. Ann Surg, 1979, 189(2):205-208. |
[21] |
Sultana A, Tudur SC, Cunningham D, et al. Systematic review, including meta-analyses, on the management of locally advanced pancreatic cancer using radiation/combined modality therapy[J]. Br J Cancer, 2007, 96(8):1183-1190.
doi: 10.1038/sj.bjc.6603719 URL |
[22] |
Huguet F, Girard N, Guerche CS, et al. Chemoradiothe-rapy in the management of locally advanced pancreatic carcinoma: a qualitative systematic review[J]. J Clin Oncol, 2009, 27(13):2269-2277.
doi: 10.1200/JCO.2008.19.7921 URL |
[23] |
Wu L, Zhou Y, Fan Y, et al. Consolidative chemoradiotherapy after induced chemotherapy is an optimal regimen for locally advanced pancreatic cancer[J]. Front Oncol, 2019, 9:1543.
doi: 10.3389/fonc.2019.01543 URL |
[24] |
Schneider BJ, Ben-Josef E, McGinn CJ, et al. Capecitabine and radiation therapy preceded and followed by combination chemotherapy in advanced pancreatic cancer[J]. Int J Radiat Oncol Biol Phys, 2005, 63(5):1325-1330.
doi: 10.1016/j.ijrobp.2005.04.030 URL |
[25] |
Lawrence TS, Eisbruch A, Shewach DS. Gemcitabine-mediated radiosensitization[J]. Semin Oncol, 1997, 24(2 Suppl 7):S7-S24.
pmid: 9194476 |
[26] |
Blackstock AW, Tepper JE, Niedwiecki D, et al. Cancer and leukemia group B (CALGB) 89805: phase Ⅱ chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma of the pancreas[J]. Int J Gastrointest Cancer, 2003, 34(2-3):107-116.
pmid: 15361643 |
[27] |
Cardenes HR, Moore AM, Johnson CS, et al. A phase Ⅱ study of gemcitabine in combination with radiation therapy in patients with localized, unresectable, pancreatic cancer: a Hoosier Oncology Group study[J]. Am J Clin Oncol, 2011, 34(5):460-465.
doi: 10.1097/COC.0b013e3181e9c103 URL |
[28] |
Li CP, Chao Y, Chi KH, et al. Concurrent chemoradiotherapy treatment of locally advanced pancreatic cancer: gemcitabine versus 5-fluorouracil, a randomized controlled study[J]. Int J Radiat Oncol Biol Phys, 2003, 57(1):98-104.
doi: 10.1016/S0360-3016(03)00435-8 URL |
[29] | Brasiuniene B, Juozaityte E. The effect of combined treatment methods on survival and toxicity in patients with pancreatic cancer[J]. Medicina (Kaunas), 2007, 43(9):716-725. |
[30] |
Hurt CN, Falk S, Crosby T, et al. Long-term results and recurrence patterns from SCALOP: a phaseⅡ randomised trial of gemcitabine- or capecitabine-based chemoradiation for locally advanced pancreatic cancer[J]. Br J Cancer, 2017, 116(10):1264-1270.
doi: 10.1038/bjc.2017.95 URL |
[31] |
Mahadevan A, Miksad R, Goldstein M, et al. Induction gemcitabine and stereotactic body radiotherapy for locally advanced nonmetastatic pancreas cancer[J]. Int J Radiat Oncol Biol Phys, 2011, 81(4):e615-e622.
doi: 10.1016/j.ijrobp.2011.04.045 URL |
[32] |
Huguet F, Andre T, Hammel P, et al. Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase Ⅱ and Ⅲ studies[J]. J Clin Oncol, 2007, 25(3):326-331.
doi: 10.1200/JCO.2006.07.5663 URL |
[33] |
Hammel P, Huguet F, van Laethem JL, et al. Effect of chemoradiotherapy vs. chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: the LAP07 randomized clinical trial[J]. JAMA, 2016, 315(17):1844-1853.
doi: 10.1001/jama.2016.4324 URL |
[34] |
Perri G, Prakash L, Qiao W, et al. Response and survival associated with first-line FOLFIRINOX vs. gemcitabine and nab-paclitaxel chemotherapy for localized pancreatic ductal adenocarcinoma[J]. JAMA Surg, 2020, 155(9):832-839.
doi: 10.1001/jamasurg.2020.2286 URL |
[35] |
Gemenetzis G, Groot VP, Blair AB, et al. Survival in locally advanced pancreatic cancer after neoadjuvant the-rapy and surgical resection[J]. Ann Surg, 2019, 270(2):340-347.
doi: 10.1097/SLA.0000000000002753 pmid: 29596120 |
[36] |
Hayashi T, Nakamura T, Kimura Y, et al. Phase 2 study of neoadjuvant treatment of sequential S-1-based concurrent chemoradiation therapy followed by systemic chemotherapy with gemcitabine for borderline resectable pancreatic adenocarcinoma(HOPS-BR 01)[J]. Int J Radiat Oncol Biol Phys, 2019, 105(3):606-617.
doi: 10.1016/j.ijrobp.2019.07.004 URL |
[37] |
Li Y, Feng Q, Jin J, et al. Experts′ consensus on intra-operative radiotherapy for pancreatic cancer[J]. Cancer Lett, 2019, 449:1-7.
doi: 10.1016/j.canlet.2019.01.038 URL |
[1] | ZHANG Hongzhan, ZHANG Kai. Current status and prospect of endoscopic photodynamic therapy for unresectable extrahepatic cholangiocarcinoma and ampullary carcinoma [J]. Journal of Surgery Concepts & Practice, 2023, 28(04): 316-320. |
[2] | GAO Pan, CAI Yunqiang, PENG Bing. Function-preserving laparoscopic resection of pancreatic head and duodenal papilla tumors [J]. Journal of Surgery Concepts & Practice, 2023, 28(03): 190-196. |
[3] | YU Lan, ZHANG Yongyi, HUANG Lei, WAN Xin, JIANG Shengyao, TANG Sijing, ZHANG Jun, HU Weiguo. Risk factors of severe postoperative complications in elderly patients with pancreaticoduodenectomy [J]. Journal of Surgery Concepts & Practice, 2023, 28(02): 139-146. |
[4] | XIE Xuehai, YANG Yinmo. Evaluation and technical key points of pancreaticojejunostomy [J]. Journal of Surgery Concepts & Practice, 2022, 27(01): 1-5. |
[5] | HE Min, LIU Yingbin. Resectable pancreatic cancer: diagnosis criterion, treatment and controversy [J]. Journal of Surgery Concepts & Practice, 2022, 27(01): 6-10. |
[6] | SHI Yihua, JI Shunrong, XU Xiaowu, YU Xianjun. Minimally invasive enucleation of pancreatic tumor: technical note and thinking [J]. Journal of Surgery Concepts & Practice, 2022, 27(01): 14-18. |
[7] | LI Ji, FU Deliang, NI Quanxing. Surgical decision making for pancreatic cystic neoplasm: selection of local enucleation [J]. Journal of Surgery Concepts & Practice, 2022, 27(01): 19-21. |
[8] | WANG Chong, CHENG Shi. Consensus and controversy: preoperative biliary drainage for resectable pancreatic cancer [J]. Journal of Surgery Concepts & Practice, 2022, 27(01): 30-33. |
[9] | WANG Wei, HUA Jie. Common vascular variations and coping strategies in pancreaticoduodenectomy [J]. Journal of Surgery Concepts & Practice, 2022, 27(01): 34-38. |
[10] | WEI Jishu, HUANG Shimeng. Perineural invasion and neural plasticity in pancreatic cancer: study history and current treatment [J]. Journal of Surgery Concepts & Practice, 2022, 27(01): 42-45. |
[11] | YANG Chunxue, XU Haimin, DA Qian. Clinicopathological features of pancreatic intraductal oncocytic papillary neoplasm: a report of 5 cases [J]. Journal of Surgery Concepts & Practice, 2022, 27(01): 52-57. |
[12] | XU Yu, ZHANG Junfeng, HUA Rong. Use of octreotide for prevention of pancreatic leak after pancreatoduodenectomy: study progress [J]. Journal of Surgery Concepts & Practice, 2022, 27(01): 83-86. |
[13] | LUO Danyang, GAO Yiming. Study on oral microflora related to pancreatic cancer [J]. Journal of Surgery Concepts & Practice, 2021, 26(01): 84-86. |
[14] | DING Fangmi, LIU Zhendong. Forkhead box D1 promotes invasion and metastasis of pancreatic cancer via extracellular signal-regulated kinase pathway [J]. Journal of Surgery Concepts & Practice, 2020, 25(06): 486-492. |
[15] | QIAN Lihan, SHN Baiyong. Research progress on comprehensive treatment of locally advanced pancreatic cancer [J]. Journal of Surgery Concepts & Practice, 2020, 25(05): 442-446. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||